INTACT2

The purpose of the INTACT-2 study is to test if two treatments – iron (infused into the veins) and a man-made version of a hormone normally produced by the body (recombinant EPO, given as an injection under the skin) – can successfully treat anaemia and improve physical aspects of health-related quality of life, in patients after they leave ICU.

Chief Investigator: Dr David M Griffith

Number and location of participating sites / geographical scope (by region/ country): UK 25 sites

EudraCT number: N/A

ISRCTN number: N/A

Funder: NIHR / MRC Efficacy and Mechanism Evaluation

Start and End date

Of grant award: August 2024

Of recruitment: May 2025

Current Status: In set-up

UK GDPR privacy statement: UK GDPR Privacy Statement: Information can be found in our Patient Information Sheets.

You can find out more about how we use your information:

at www.hra.nhs.uk/patientdataandresearch
by asking one of the research team
by sending an email to the Data Protection Officer: dpo@ed.ac.uk

Sponsor: ACCORD, Usher Building, The University of Edinburgh, 5-7 Little France Road, Edinburgh BioQuarter - Gate 3, Edinburgh EH16 4UX http://accord.scot/

Chief Investigator: David M Griffith, Centre for Population Health Sciences, The Usher Institute, Usher Building, The University of EdinburghBioQuarter, Gate 5-7, 3 Little France Road, Edinburgh, EH16 4UX

Email: INTACT2.trial@ed.ac.uk

ECTU Involvement: Trial management / Statistics / Health Economics / Database and randomisation service provision

(UKCRC)

This article was published on 2025-02-05